Type 1 diabetes: Islet inflammation - the contribution of cytokines and beta cells

Drug Discovery Today: Disease Mechanisms

Volumn 3, Issue 3, 2006, Pages 367-372

  Gusdon, Aaron M ^a   Corbett, John A ^b   Mathews, Clayton E ^a  

^a Diabetes Institute   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CELL ADHESION MOLECULE; CHECKPOINT KINASE 1; CYTOKINE; FREE RADICAL; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 1; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNITY; CELL DEATH; CELL DESTRUCTION; CELL KILLING; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 33847189211     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2006.09.010     Document Type: Review

References (65)

1. Rosmalen J.G., et al. Subsets of macrophages and dendritic cells in nonobese diabetic mouse pancreatic inflammatory infiltrates: correlation with the development of diabetes. Lab. Invest. 80 (2000) 23-30
2. Charre S., et al. Abnormalities in dendritic cell and macrophage accumulation in the pancreas of nonobese diabetic (NOD) mice during the early neonatal period. Histol. Histopathol. 17 (2002) 393-401
3. Jansen A., et al. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes 43 (1994) 667-675
4. Andre I., et al. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc. Natl. Acad. Sci. U S A 93 (1996) 2260-2263
5. Haskins K., et al. Oxidative stress in type 1 diabetes. Ann. N. Y. Acad. Sci. 1005 (2003) 43-54
6. Bouma G., et al. Evidence for an enhanced adhesion of DC to fibronectin and a role of CCL19 and CCL21 in the accumulation of DC around the pre-diabetic islets in NOD mice. Eur. J. Immunol. 35 (2005) 2386-2396
7. Kikuchi K., et al. CCR7 ligand-enhanced phagocytosis of various antigens in mature dendritic cells-time course and antigen distribution different from phagocytosis in immature dendritic cells. Microbiol. Immunol. 49 (2005) 535-544
8. Bouma G., et al. NOD mice have a severely impaired ability to recruit leukocytes into sites of inflammation. Eur. J. Immunol. 35 (2005) 225-235
9. Ploix C., et al. A ligand for the chemokine receptor CCR7 can influence the homeostatic proliferation of CD4 T cells and progression of autoimmunity. J. Immunol. 167 (2001) 6724-6730
10. Fox C.J., and Danska J.S. Independent genetic regulation of T-cell and antigen-presenting cell participation in autoimmune islet inflammation. Diabetes 47 (1998) 331-338
11. Steer S.A., et al. Interleukin-1 stimulates beta-cell necrosis and release of the immunological adjuvant HMGB1. PLoS Med. 3 (2005) e17
12. Kröncke K.-D., et al. Activated macrophages kill pancreatic syngeneic islet cells via arginine-dependent nitric oxide generation. Biochem. Biophys. Res. Commun. 175 (1991) 752-758
13. Lenzen S., et al. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic. Biol. Med. 20 (1996) 463-466
14. Tiedge M., et al. Relation between antioxidant enzyme gene-expression and antioxidative defense status of insulin-producing cells. Diabetes 46 (1997) 1733-1742
15. Mathews C.E., et al. Unusual resistance of ALR/Lt beta cells to autoimmune destruction: role for beta cell expressed resistance determinants. Proc. Natl. Acad. Sci. USA 98 (2001) 235-240
16. Mathews C.E., et al. Mechanisms underlying resistance of pancreatic islets from ALR/Lt mice to cytokine-induced destruction. J. Immunol. 175 (2005) 1248-1256
17. Suarez-Pinzon W.L., et al. An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in NOD mice. J. Autoimmun. 16 (2001) 449-455
18. Mathews C., and Leiter E. Resistance of ALR/Lt Islets to free radical mediated diabetogenic stress is inherited as a dominant trait. Diabetes 48 (1999) 2189-2196
19. Di Matteo M.A., et al. Superoxide, nitric oxide, peroxynitrite and cytokine combinations all cause functional impairment and morphological changes in rat islets of Langerhans and insulin secreting cell lines, but dictate cell death by different mechanisms. Apoptosis 2 (1997) 164-177
20. Mathews C., and Leiter E. Constitutive differences in anti-oxidant defense status distinguish alloxan resistant (ALR/Lt) and alloxan susceptible (ALS/Lt) mice. Free Radic. Biol. Med. 27 (1999) 449-455
21. Delaney C.A., et al. Nitric oxide rather than superoxide or peroxynitrite inhibits insulin secretion and causes DNA damage in HIT-T15 cells. Adv. Exp. Med. Biol. 426 (1997) 335-339
22. Shiva S., et al. Nitric oxide partitioning into mitochondrial membranes and the control of respiration at cytochrome c oxidase. Proc. Natl. Acad. Sci. USA 98 (2001) 7212-7217
23. Turko I.V., et al. Protein tyrosine nitration in the mitochondria from diabetic mouse heart. Implications to dysfunctional mitochondria in diabetes. J. Biol. Chem. 278 (2003) 33972-33977
24. Scarim A.L., et al. Irreversible inhibition of metabolic function and islet destruction after a 36-hour exposure to interleukin-1-beta. Endocrinology 138 (1997) 5301-5307
25. Brown G.C., and Borutaite V. Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim. Biophys. Acta 1658 (2004) 44-49
26. Rovere-Querini P., et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5 (2004) 825-830
27. Rabinovitch A., et al. Cytotoxic effects of cytokines on rat islets: evidence for involvement of free radicals and lipid peroxidation. Diabetologia 35 (1992) 409-413
28. Corbett J.A., and Mcdaniel M.L. Intraislet release of interleukin 1 inhibits beta cell function by inducing beta cell expression of inducible nitric oxide synthase. J. Exp. Med. 181 (1995) 559-568
29. Heitmeier M.R., et al. Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1. J. Biol. Chem. 272 (1997) 13697-13704
30. Mandrup-Poulsen T., et al. What are the types and cellular sources of free radicals in the pathogenesis of insulin dependent (type 1) diabetes mellitus?. Diabetologia 36 (1993) 470-473
31. Corbett J.A., et al. IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans - activation of cyclooxygenase by nitric oxide. Biochemistry 32 (1993) 13767-13770
32. Lakey J.R., et al. Peroxynitrite is a mediator of cytokine-induced destruction of human pancreatic islet beta cells. Lab. Invest. 81 (2001) 1683-1692
33. Nakayama M., et al. Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem. Biophys. Res. Commun. 332 (2005) 927-933
34. Oliveira H.R., et al. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes 52 (2003) 1457-1463
35. Reimers J., et al. Strain-dependent differences in sensitivity of rat beta-cells to interleukin 1 beta in vitro and in vivo: association with islet nitric oxide synthesis. Diabetes 45 (1996) 771-778
36. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 14 (1998) 129-151
37. Thomas H.E., et al. Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes 51 (2002) 311-316
38. Rabinovitch A., and Suarez-Pinzon W.L. Cytokines and their roles in pancreatic islet beta cell destruction and insulin dependent diabetes mellitus. Biochem. Pharmacol. 55 (1998) 1139-1149
39. Andersson A.K., et al. Cytokine-induced inhibition of insulin release from mouse pancreatic beta-cells deficient in inducible nitric oxide synthase. Biochem. Biophys. Res. Commun. 281 (2001) 396-403
40. Scarim A.L., et al. Heat shock inhibits cytokine-induced nitric oxide synthase expression by rat and human islets. Endocrinology 139 (1998) 5050-5057
41. Thomas H.E., et al. Perturbations in nuclear factor-kappaB or c-Jun N-terminal kinase pathways in pancreatic beta cells confer susceptibility to cytokine-induced cell death. Immunol. Cell Biol. 84 (2006) 20-27
42. Mabley J.G., et al. NFkappaB1 (p50)-deficient mice are not susceptible to multiple low-dose streptozotocin-induced diabetes. J. Endocrinol. 173 (2002) 457-464
43. Ohkawa T., et al. Stimulation of hyaluronan synthesis by tumor necrosis factor-alpha is mediated by the p50/p65 NF-kappa B complex in MRC-5 myofibroblasts. Biochim. Biophys. Acta 1448 (1999) 416-424
44. Holden N.S., et al. ICAM-1 expression is highly NF-κB-dependent in A549 cells: no role for ERK or p38 MAPK. Eur. J. Biochem. 271 (2004) 785-791
45. Martin S., et al. Soluble forms of intercellular adhesion molecule-1 inhibit insulitis and onset of autoimmune diabetes [in process citation]. Diabetologia 41 (1998) 1298-1303
46. Martin S., et al. Dominant role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in non-obese diabetic mice. J. Autoimmun. 17 (2001) 109-117
47. Huang M., et al. Alpha L-integrin I domain cyclic peptide antagonist selectively inhibits T cell adhesion to pancreatic islet microvascular endothelium. Am. J. Physiol. Gastrointest Liver Physiol. 288 (2005) G67-G73
48. Oguchi T., and Ishiguro N. Differential stimulation of three forms of hyaluronan synthase by TGF-beta, IL-1beta, and TNF-alpha. Connect. Tissue Res. 45 (2004) 197-205
49. Savinov A.Y., et al. Inhibition of membrane type-1 matrix metalloproteinase by cancer drugs interferes with the homing of diabetogenic T cells into the pancreas. J. Biol. Chem. 280 (2005) 27755-27758
50. Itoh N., et al. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186 (1997) 613-618
51. Savinov A.Y., et al. Contribution of Fas to diabetes development. Proc. Natl. Acad. Sci. U S A 100 (2003) 628-632
52. Amrani A., et al. IL-1 alpha, IL-1 beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes. J. Clin. Invest. 105 (2000) 459-468
53. Kuttler B., et al. Aminoguanidine downregulates expression of cytokine-induced Fas and inducible nitric oxide synthase but not cytokine-enhanced surface antigens of rat islet cells. Biochem. Pharmacol. 66 (2003) 2437-2448
54. Thomas H.E., et al. IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J. Clin. Invest. 102 (1998) 1249-1257
55. Hultgren B., et al. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 45 (1996) 812-817
56. Serreze D.V., et al. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 49 (2000) 2007-2011
57. Serreze D., et al. Th1 to Th2 cytokine shifts in NOD mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J. Immunol. 166 (2001) 1352-1359
58. Kanagawa O., et al. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci. J. Immunol. 164 (2000) 3919-3923
59. Schott W.H., et al. Caspase-1 is not required for type 1 diabetes in the NOD mouse. Diabetes 53 (2004) 99-104
60. Thomas H.E., et al. IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes 53 (2004) 113-121
61. Savinov A.Y., et al. IFN-gamma affects homing of diabetogenic T cells. J. Immunol. 167 (2001) 6637-6643
62. Pakala S.V., et al. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J. Exp. Med. 189 (1999) 1053-1062
63. Mathews C.E., et al. Re-evaluation of the major histocompatibility complex genes of the NOD-progenitor CTS/Shi strain. Diabetes 49 (2000) 131-134
64. Piganelli J.D., et al. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 51 (2002) 347-355
65. Corbett J.A., and McDaniel M.L. The use of aminoguanidine, a selective iNOS inhibitor, to evaluate the role of nitric oxide in the development of autoimmune. Diabetes Methods 10 (1996) 21-30